Eris Lifesciences Ltd.

NSE: ERIS | BSE: 540596 | ISIN: INE406M01024 | Industry: Pharmaceuticals
| Expensive Rocket
1581.8000 -33.90 (-2.10%)
NSE May 30, 2025 15:31 PM
Volume: 178.1K
 

1581.80
-2.10%
Systematix Group
Focus on branded prescription based pharmaceutical products catering to lifestyle related disorders: Eris has Develop, Manufacture and Commercialize branded prescription based pharmaceuticals products in select chronic and acute therapeutic areas, like Cardiovascular, Anti-Diabetics, Vitamins, Gastroenterology, Anti-Infectives, & Gynaecology. In FY17, they generated 65.6% of their revenues from the chronic category of the IPM. The chronic category accounted for 34.3% of the IPM in FY17 compared to 31.4% of the IPM in FY13, representing growth at a CAGR of 14.3%. They have identified, developed and are marketing products in the acute category, which are connected to...
Eris Lifesciences Ltd. has an average target of 1502.67 from 3 brokers.
More from Eris Lifesciences Ltd.
Recommended